TABLE 1

Study details for clinical data used during validation and optimization of a whole-body PBPK model for prediction of propofol in vivo clearance and blood concentration-time profiles from in vitro CL_int data

Data are presented as mean (± S.D.) unless otherwise specified.

Study	Status of Patients	Dose Type	Dose Level	Subjects	Body Weight	Age	Male
			mg/kg	n	kg	yr	%
Doenicke et al. (1997)	Intact	Intravenous bolus	2	12	ND	24–42^{^a}	100
Doenicke et al. (1997)	Intact	Intravenous bolus	2	12	ND	24–42^{^a}	100
Gepts et al. (1987)	Intact	Intravenous infusion over 2 h	6	6	75.0 (7.2)	60.3 (4.9)	100
			12	6	65.5 (7.9)	50.6 (14.7)	67
			18	6	61.6 (8.8)	39.8 (10.0)	50
Veroli et al. (1992)	Anhepatic	Intravenous bolus	0.5	10	60.0 (7.0)	38.0 (ND)	ND

ND, not detailed; PBPK, physiologically based pharmacokinetic.
↵^a Mean age not detailed; age range of subjects presented instead